A step-by-step protocol for isolation and flow cytometry analysis of porcine cardiac valve leaflets Authors: Herra Javed, Zachary Waldrip, Anshaal Furrukh, Eli Contorno, Louis Steen, John Lowery, David Irby, Randall Rainwater, Kristin Whitworth, Marie Burdine, T. Konrad Rajab Published: 2025 ABSTRACT SummaryFlow cytometry analysis of GFP-expressing porcine valves is an indispensable model for studying partial heart transplantation immunobiology. Here, we present a protocol for the systematic isolation and phenotypic characterization of leaflet-derived cells from pulmonary and aortic valves. We describe steps for valve procurement, enzymatic digestion to single-cell suspension, preparation of samples with antibody, and viability staining and gating strategies for accurate and reproducible flow cytometric analysis. This approach provides valuable insight into valve biology and supports rigorous evaluation of cellular dynamics in experimental transplantation models. Before you begin Due to the unique similarities that swine share with humans, they have become the favored animal model for cardiovascular research, including research involving the heart valves.1 The establishment of techniques for various isolation and characterization tests means that a range of options can be used to gain data on porcine valves in the research setting.2,3 However, no established protocol for flow cytometry of porcine valves currently exists. This protocol was developed in order to research the immune response and related immunosuppressive therapy associated with partial heart transplantation (PHT). This procedure involves the transplant of a viable truncal valve root harvested from a donor into a recipient.4 Flow cytometry is necessary for the investigation of this immune response as it allows for the number of infiltrating cells such as T-cells to be quantified via the staining protocol described here. The method described is also unique due to the use of green-fluorescent protein (GFP) positive porcine models. The addition of ubiquitously expressed GFP through association with a p-CAGG promoter significantly alters the tissue’s background fluorescence, which means there is potential for overlap in the GFP signal and the signal of positive stains for viability, CD31, and CD3. Due to this, a procedure specifically for GFP was established to ensure the altered background fluorescence did not hinder the accurate interpretation of staining results. Innovation This protocol establishes the first validated flow cytometry workflow for quantitative and phenotypic analysis of porcine semilunar valve leaflets. Valve tissue presents major technical challenges due to its dense extracellular matrix, low cell yield, and mixed endothelial and stromal composition. Through systematic optimization of digestion, gating hierarchy and antibody selection, this method achieves high single-cell recovery and reproducible identification of CD31+ endothelial and CD3+ immune cells. This protocol provides a reproducible framework for valve-specific immune profiling, enabling precise assessment of graft viability, immune infiltration, and donor cell persistence in porcine transplantation models. The protocol has been independently performed by four researchers, across multiple tissue samples, demonstrating replicability of the method. Animal handling and biohazard training Before working on this protocol, the individuals must have received the appropriate training for animal handling, and safety training for proper handling and disposal of the hazardous biological materials. Institutional permissions In this study, animal experiments were conducted per U.S. legislation and with required approvals from the Institutional Animal Care and Use Committee (IACUC), protocol reference number: IPROTO202300000160. Any experiments on porcine species must be performed in accordance with relevant institutional and national guidelines and regulations. Ensure that permission exists from the relevant institutions before starting the experiments. Thermo Fisher Scientific Attune NxT flow cytometry setup Timing: 30 min Timing: 30 min The Attune NxT used in this protocol is equipped with a total of four lasers, a violet laser with a wavelength of 405 nm, a blue laser with a wavelength of 488 nm, a green laser with a wavelength of 532 nm, a red laser with a wavelength of 638 nm and 16 total detection channels including the forward and side scatter channels (Table 1).Table 1Laser settings for Thermo Fisher Scientific Attune NxT flow cytometerLaserWavelength (nm)Power (mW)Violet405100Blue488100Yellow561100Red638140 Table 1Laser settings for Thermo Fisher Scientific Attune NxT flow cytometerLaserWavelength (nm)Power (mW)Violet405100Blue488100Yellow561100Red638140 Laser settings for Thermo Fisher Scientific Attune NxT flow cytometer For compensation use UltraComp eBeads Plus from Thermo Fisher Scientific.1.Power on the flow cytometer and allow the system to complete its self-diagnostic checks to ensure all components, including lasers, fluidics, and detectors, are functioning optimally before proceeding.2.Refill all fluid and buffers to prime all fluidic tanks, ensuring uninterrupted operation.3.Verify instrument performance and calibrate using standardized quality control beads, which confirm detector sensitivity, photomultiplier tube voltage alignment, and laser delay accuracy to maintain reproducibility across experiments.4.Create a new experiment.5.Define parameters such as sample volume, flow rate, and acquisition mode to tailor the setup to the specific requirements of your experimental design.6.Adjust PMT voltages based on preferred parameters and signal intensity.7.Configure graphical data displays by generating histograms for single-parameter analysis and dot plots for multi-parameter comparisons, such as forward scatter-height (FSC-H) versus side scatter-height (SSC-H), to visualize population distributions.8.Set acquisition thresholds on a primary parameter, such as forward scatter-height (FSC-H), to exclude subcellular debris and electronic noise, then fine-tune detector voltages and gains to optimize signal resolution.9.Define analytical gates and regions by drawing boundaries on plots to isolate specific cell populations of interest, establishing a sequential gating strategy that prioritizes singlet selection, live cell identification, and phenotypic subset analysis.Note: Acquisition Software: Attune Nxt Software (Thermo Fisher Scientific, Walton, MA, USA) and FlowJo (BDBiosciences, Ashland, OR, USA). 1.Power on the flow cytometer and allow the system to complete its self-diagnostic checks to ensure all components, including lasers, fluidics, and detectors, are functioning optimally before proceeding. Power on the flow cytometer and allow the system to complete its self-diagnostic checks to ensure all components, including lasers, fluidics, and detectors, are functioning optimally before proceeding. 2.Refill all fluid and buffers to prime all fluidic tanks, ensuring uninterrupted operation. Refill all fluid and buffers to prime all fluidic tanks, ensuring uninterrupted operation. 3.Verify instrument performance and calibrate using standardized quality control beads, which confirm detector sensitivity, photomultiplier tube voltage alignment, and laser delay accuracy to maintain reproducibility across experiments. Verify instrument performance and calibrate using standardized quality control beads, which confirm detector sensitivity, photomultiplier tube voltage alignment, and laser delay accuracy to maintain reproducibility across experiments. 4.Create a new experiment. Create a new experiment. 5.Define parameters such as sample volume, flow rate, and acquisition mode to tailor the setup to the specific requirements of your experimental design. Define parameters such as sample volume, flow rate, and acquisition mode to tailor the setup to the specific requirements of your experimental design. 6.Adjust PMT voltages based on preferred parameters and signal intensity. Adjust PMT voltages based on preferred parameters and signal intensity. 7.Configure graphical data displays by generating histograms for single-parameter analysis and dot plots for multi-parameter comparisons, such as forward scatter-height (FSC-H) versus side scatter-height (SSC-H), to visualize population distributions. Configure graphical data displays by generating histograms for single-parameter analysis and dot plots for multi-parameter comparisons, such as forward scatter-height (FSC-H) versus side scatter-height (SSC-H), to visualize population distributions. 8.Set acquisition thresholds on a primary parameter, such as forward scatter-height (FSC-H), to exclude subcellular debris and electronic noise, then fine-tune detector voltages and gains to optimize signal resolution. Set acquisition thresholds on a primary parameter, such as forward scatter-height (FSC-H), to exclude subcellular debris and electronic noise, then fine-tune detector voltages and gains to optimize signal resolution. 9.Define analytical gates and regions by drawing boundaries on plots to isolate specific cell populations of interest, establishing a sequential gating strategy that prioritizes singlet selection, live cell identification, and phenotypic subset analysis. Define analytical gates and regions by drawing boundaries on plots to isolate specific cell populations of interest, establishing a sequential gating strategy that prioritizes singlet selection, live cell identification, and phenotypic subset analysis. Note: Acquisition Software: Attune Nxt Software (Thermo Fisher Scientific, Walton, MA, USA) and FlowJo (BDBiosciences, Ashland, OR, USA). Design flow cytometry panels Timing: 30 min 10.Use two separate panels for easy and effective analysis of extracellular antibody markers and the health status of the single cell population. Validated panels for identification of tumor endothelial cells and tumor-infiltrating CD8+ T cells are detailed in Tables 2 and Table 3.Table 2Panel for flow cytometry analysis of extracellular antigensMarkerFluorophoreFinal dilutionIgG concentrationVolume for 100 μL sampleCD3StarBright Violet 4401:20200 μg/ml5 μLCD31Alexa Fluor 6471:1050 μg/ml10 μLTable 3Panel for flow cytometry analysis of apoptotic and viable cellsMarkerFluorophoreFinal dilutionVolume for 100 μL sampleAnnexin VeFluor 4501:205 μLViability7-AAD1:205 μLViabilityPropidium Iodide1:205 μL Note: Ensuring appropriate panel design is crucial to avoid spectral overlap. Our experiment used green-fluorescent protein (GFP) positive BL1 (530/30) porcine models hence the choosing of the antibodies required special consideration. Note: Use any panel builder to design fluorochrome combinations. We used Thermo Fisher Scientific Panel builder to select appropriate fluorochromes. Timing: 30 min 10.Use two separate panels for easy and effective analysis of extracellular antibody markers and the health status of the single cell population. Validated panels for identification of tumor endothelial cells and tumor-infiltrating CD8+ T cells are detailed in Tables 2 and Table 3.Table 2Panel for flow cytometry analysis of extracellular antigensMarkerFluorophoreFinal dilutionIgG concentrationVolume for 100 μL sampleCD3StarBright Violet 4401:20200 μg/ml5 μLCD31Alexa Fluor 6471:1050 μg/ml10 μLTable 3Panel for flow cytometry analysis of apoptotic and viable cellsMarkerFluorophoreFinal dilutionVolume for 100 μL sampleAnnexin VeFluor 4501:205 μLViability7-AAD1:205 μLViabilityPropidium Iodide1:205 μL Use two separate panels for easy and effective analysis of extracellular antibody markers and the health status of the single cell population. Validated panels for identification of tumor endothelial cells and tumor-infiltrating CD8+ T cells are detailed in Tables 2 and Table 3.Table 2Panel for flow cytometry analysis of extracellular antigensMarkerFluorophoreFinal dilutionIgG concentrationVolume for 100 μL sampleCD3StarBright Violet 4401:20200 μg/ml5 μLCD31Alexa Fluor 6471:1050 μg/ml10 μLTable 3Panel for flow cytometry analysis of apoptotic and viable cellsMarkerFluorophoreFinal dilutionVolume for 100 μL sampleAnnexin VeFluor 4501:205 μLViability7-AAD1:205 μLViabilityPropidium Iodide1:205 μL Table 2Panel for flow cytometry analysis of extracellular antigensMarkerFluorophoreFinal dilutionIgG concentrationVolume for 100 μL sampleCD3StarBright Violet 4401:20200 μg/ml5 μLCD31Alexa Fluor 6471:1050 μg/ml10 μL Panel for flow cytometry analysis of extracellular antigens Table 3Panel for flow cytometry analysis of apoptotic and viable cellsMarkerFluorophoreFinal dilutionVolume for 100 μL sampleAnnexin VeFluor 4501:205 μLViability7-AAD1:205 μLViabilityPropidium Iodide1:205 μL Panel for flow cytometry analysis of apoptotic and viable cells Note: Ensuring appropriate panel design is crucial to avoid spectral overlap. Our experiment used green-fluorescent protein (GFP) positive BL1 (530/30) porcine models hence the choosing of the antibodies required special consideration. Note: Use any panel builder to design fluorochrome combinations. We used Thermo Fisher Scientific Panel builder to select appropriate fluorochromes. Prepare reagents and buffers Timing: 30 min 11.Ensure the availability of all reagents listed in the key resources table and materials and equipment section.12.Prepare the digest solution:a.Prepare the Digest solution according to the materials and equipment section and as described in the step-by-step method details section, steps 5–6.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Note: The Digest solution has to be prepared fresh before each experiment. It can be prepared up to 24 hours prior to the experiment, provided it is kept cold at all steps. 13.Prepare 1X Binding Buffer.a.Prepare the 1X Binding Buffer according to the materials and equipment section and as described in the step-by-step method details section, step 7.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Timing: 30 min 11.Ensure the availability of all reagents listed in the key resources table and materials and equipment section. Ensure the availability of all reagents listed in the key resources table and materials and equipment section. 12.Prepare the digest solution:a.Prepare the Digest solution according to the materials and equipment section and as described in the step-by-step method details section, steps 5–6.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Prepare the digest solution:a.Prepare the Digest solution according to the materials and equipment section and as described in the step-by-step method details section, steps 5–6.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). a.Prepare the Digest solution according to the materials and equipment section and as described in the step-by-step method details section, steps 5–6.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Prepare the Digest solution according to the materials and equipment section and as described in the step-by-step method details section, steps 5–6.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Store the prepared solution at 4°C for short-term use (up to 24 hours). Note: The Digest solution has to be prepared fresh before each experiment. It can be prepared up to 24 hours prior to the experiment, provided it is kept cold at all steps. 13.Prepare 1X Binding Buffer.a.Prepare the 1X Binding Buffer according to the materials and equipment section and as described in the step-by-step method details section, step 7.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Prepare 1X Binding Buffer.a.Prepare the 1X Binding Buffer according to the materials and equipment section and as described in the step-by-step method details section, step 7.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). a.Prepare the 1X Binding Buffer according to the materials and equipment section and as described in the step-by-step method details section, step 7.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Prepare the 1X Binding Buffer according to the materials and equipment section and as described in the step-by-step method details section, step 7.i.Store the prepared solution at 4°C for short-term use (up to 24 hours). i.Store the prepared solution at 4°C for short-term use (up to 24 hours). Store the prepared solution at 4°C for short-term use (up to 24 hours). Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD31 monoclonal antibodymouse anti-pig CD31:Alexa Fluor 647 1:10Bio-RadCat# MC-A17-46A647RRID:AB_3100514CD3 monoclonal antibodymouse anti-pig CD3:StarBright Violet 440 1:20Bio-RadCat# MC-A59-51SBV440RRID:AB_3101178Chemicals, peptides, and recombinant proteinsCollagenase PRocheCat# 11-213-857001RPMI 1640 mediumGibcoCat# 11-875-093Belzer UW cold storage solutionBridge to LifeCat# BUW-0011x phosphate-buffered salineSigma-AldrichCat# P2-272-1LCritical commercial assaysPropidium iodide (PI)InvitrogenCat# P3-5667-AADBD BiosciencesCat# 55-992-5Annexin V apoptosis detection kits eFluor 450,7-AADInvitrogenCat# 88-8006-74Flow cytometry staining bufferInvitrogenCat# 50-112-9748UltraComp eBeads Plus compensation beadsInvitrogenCat# 56-421-9Human BD Fc blockBD PharmingenCat# 56-421-9Experimental models: Organisms/strainsPorcine: Yorkshire GFP/WT (6–10 weeks old, male/female)National Swine Resource and Research Center (NSRRC)N/ASoftware and algorithmsAttune Nxt SoftwareThermo Fisher ScientificVersion 2.7 https://downloads.thermofisher.com/Instrument_Software/Attune/7.1/FlowJo v.10.8.1BD BiosciencesRRID:SCR_008520https://flowjo.com/flowjo10/downloadR version 4.2.2The R FoundationRRID:SCR_001905https://cran.r-project.org/OtherFlow cytometerThermo Fisher Scientific/Attune NxtModel# Attune NxTCat# A2-485-8CytKick autosamplerThermo Fisher ScientificCat# A4-290-1Sorvall X1 Pro-MDThermo Fisher ScientificCat#75-009-220RRID:SCR_020817IMP180 incubator benchtop modelThermo Fisher ScientificCat# 51-031-562Incubating microplate shakerFisherbrandCat# 02-217-759Tube revolver rotatorThermo Fisher ScientificCat# 88-881-001Weighing scaleOhausCat# 30-253-018PipetteEppendorfCat# 22-313-00004Sterile cell strainers 70 μMFisher ScientificCat# 22-363-54896-well V-bottom platesCorningCat# 33-63Stainless steel scalpel #10 bladeFisherbrandCat# 13-812-230Metzenbaum scissorsFisher ScientificCat# 08-940Falcon 50 mL centrifuge tubesCorningCat# CL-S35-2070Falcon 15 mL centrifuge tubesCorningCat# CL-S35-2099Eppendorf 1.5 mL microtubeEppendorfCat# 02-236-4111Petri dishesFisher ScientificCat# FB-087-5713Non-filtered 10 μL pipette tipsFisherbrandCat# 02-707-436Non-filtered 200 μL pipette tipsFisherbrandCat# 02-707-46Non-filtered 1,000 μL pipette tipsFisherbrandCat# 02-707-459SpatulaEiscoCat# S0-123-08Weigh boatsFisherbrandCat# 08-732-116 REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD31 monoclonal antibodymouse anti-pig CD31:Alexa Fluor 647 1:10Bio-RadCat# MC-A17-46A647RRID:AB_3100514CD3 monoclonal antibodymouse anti-pig CD3:StarBright Violet 440 1:20Bio-RadCat# MC-A59-51SBV440RRID:AB_3101178Chemicals, peptides, and recombinant proteinsCollagenase PRocheCat# 11-213-857001RPMI 1640 mediumGibcoCat# 11-875-093Belzer UW cold storage solutionBridge to LifeCat# BUW-0011x phosphate-buffered salineSigma-AldrichCat# P2-272-1LCritical commercial assaysPropidium iodide (PI)InvitrogenCat# P3-5667-AADBD BiosciencesCat# 55-992-5Annexin V apoptosis detection kits eFluor 450,7-AADInvitrogenCat# 88-8006-74Flow cytometry staining bufferInvitrogenCat# 50-112-9748UltraComp eBeads Plus compensation beadsInvitrogenCat# 56-421-9Human BD Fc blockBD PharmingenCat# 56-421-9Experimental models: Organisms/strainsPorcine: Yorkshire GFP/WT (6–10 weeks old, male/female)National Swine Resource and Research Center (NSRRC)N/ASoftware and algorithmsAttune Nxt SoftwareThermo Fisher ScientificVersion 2.7 https://downloads.thermofisher.com/Instrument_Software/Attune/7.1/FlowJo v.10.8.1BD BiosciencesRRID:SCR_008520https://flowjo.com/flowjo10/downloadR version 4.2.2The R FoundationRRID:SCR_001905https://cran.r-project.org/OtherFlow cytometerThermo Fisher Scientific/Attune NxtModel# Attune NxTCat# A2-485-8CytKick autosamplerThermo Fisher ScientificCat# A4-290-1Sorvall X1 Pro-MDThermo Fisher ScientificCat#75-009-220RRID:SCR_020817IMP180 incubator benchtop modelThermo Fisher ScientificCat# 51-031-562Incubating microplate shakerFisherbrandCat# 02-217-759Tube revolver rotatorThermo Fisher ScientificCat# 88-881-001Weighing scaleOhausCat# 30-253-018PipetteEppendorfCat# 22-313-00004Sterile cell strainers 70 μMFisher ScientificCat# 22-363-54896-well V-bottom platesCorningCat# 33-63Stainless steel scalpel #10 bladeFisherbrandCat# 13-812-230Metzenbaum scissorsFisher ScientificCat# 08-940Falcon 50 mL centrifuge tubesCorningCat# CL-S35-2070Falcon 15 mL centrifuge tubesCorningCat# CL-S35-2099Eppendorf 1.5 mL microtubeEppendorfCat# 02-236-4111Petri dishesFisher ScientificCat# FB-087-5713Non-filtered 10 μL pipette tipsFisherbrandCat# 02-707-436Non-filtered 200 μL pipette tipsFisherbrandCat# 02-707-46Non-filtered 1,000 μL pipette tipsFisherbrandCat# 02-707-459SpatulaEiscoCat# S0-123-08Weigh boatsFisherbrandCat# 08-732-116 Step-by-step method details Preparation of materials Timing: 15 min Timing: 15 min In this section, we will detail the steps to prepare and label materials for tissue collection.1.Label a 15 mL tube for each tissue to be collected.2.Label a petri dish for each tissue to be collected.3.Label Eppendorf tubes for individual samples for digestion.4.Label 96-well plates; label one well for each cohort being tested. 1.Label a 15 mL tube for each tissue to be collected. Label a 15 mL tube for each tissue to be collected. 2.Label a petri dish for each tissue to be collected. Label a petri dish for each tissue to be collected. 3.Label Eppendorf tubes for individual samples for digestion. Label Eppendorf tubes for individual samples for digestion. 4.Label 96-well plates; label one well for each cohort being tested. Label 96-well plates; label one well for each cohort being tested. Preparation of digest solutions Timing: 30 min Timing: 30 min In this section, we outline the preparation of the Digest solution for tissue digestion to obtain single cells.5.Place pre-labeled tube on ice to cool.6.Prepare Digest solution by dissolving 2 mg Collagenase P per mL RPMI 1640 medium.a.Prepare 1 mL per valve leaflet sample.Note: Example calculation for 1 animal: 2 semilunar valves with 3 leaflets each, total 6 leaflet samples: 5.Place pre-labeled tube on ice to cool. Place pre-labeled tube on ice to cool. 6.Prepare Digest solution by dissolving 2 mg Collagenase P per mL RPMI 1640 medium.a.Prepare 1 mL per valve leaflet sample. Prepare Digest solution by dissolving 2 mg Collagenase P per mL RPMI 1640 medium.a.Prepare 1 mL per valve leaflet sample. a.Prepare 1 mL per valve leaflet sample. Prepare 1 mL per valve leaflet sample. Note: Example calculation for 1 animal: 2 semilunar valves with 3 leaflets each, total 6 leaflet samples: RPMI 1640 media: 6 ∗ 1 mL for pipetting. = 6 mL. Add 6 ∗ 2 mg Collagenase P powder. = 12 mg/6 mL (2 mg/mL).CRITICAL: Digest solution should always be prepared fresh and stored at 4°C or on ice and used within 24 h. Keep reconstituted Digest solution on ice during experiments to preserve activity.CRITICAL: Divide into single-use aliquots to prevent repeated freeze-thaw cycles. Reconstitute with any balanced salt solution buffers (e.g., PBS, calcium-containing buffers for stability). Avoid using solutions containing EDTA, as it can chelate ions necessary for activity.Note: Our group experimented with different Collagenases and found Collagenase P to be ideal for leaflet digestion to attain maximum single-cell population within appropriate times. CRITICAL: Digest solution should always be prepared fresh and stored at 4°C or on ice and used within 24 h. Keep reconstituted Digest solution on ice during experiments to preserve activity. CRITICAL: Divide into single-use aliquots to prevent repeated freeze-thaw cycles. Reconstitute with any balanced salt solution buffers (e.g., PBS, calcium-containing buffers for stability). Avoid using solutions containing EDTA, as it can chelate ions necessary for activity. Note: Our group experimented with different Collagenases and found Collagenase P to be ideal for leaflet digestion to attain maximum single-cell population within appropriate times. Preparation of 1X binding buffer Timing: 15 min Timing: 15 min In this section, we outline the preparation of the Binding Buffer provided in Annexin V Apoptosis Detection Kits (eFluor 450).Note: Each Annexin V Apoptosis Detection Kit (eFluor 450) contains 10X Binding Buffer, Annexin V eFluor 450 and 7-AAD Viability Staining Solution.7.Dilute 10X Binding Buffer to 1X using distilled water.a.Prepare 1 mL per well sample.CRITICAL: 1X Binding Buffer should always be prepared fresh and stored at 4°C or on ice and used within 24 h.Note: 1 mL 10X Binding Buffer + 9 mL distilled water = 10 mL 1X Binding Buffer.Note: Example calculation for 1 animal: 2 semilunar valves with 3 leaflets each, total 6 leaflet samples. Prepare 50 mL 1X Binding Buffer Note: Each Annexin V Apoptosis Detection Kit (eFluor 450) contains 10X Binding Buffer, Annexin V eFluor 450 and 7-AAD Viability Staining Solution. 7.Dilute 10X Binding Buffer to 1X using distilled water.a.Prepare 1 mL per well sample. Dilute 10X Binding Buffer to 1X using distilled water.a.Prepare 1 mL per well sample. a.Prepare 1 mL per well sample. Prepare 1 mL per well sample. CRITICAL: 1X Binding Buffer should always be prepared fresh and stored at 4°C or on ice and used within 24 h. Note: 1 mL 10X Binding Buffer + 9 mL distilled water = 10 mL 1X Binding Buffer. Note: Example calculation for 1 animal: 2 semilunar valves with 3 leaflets each, total 6 leaflet samples. Prepare 50 mL 1X Binding Buffer Distilled water: 5 ∗ 9 mL. = 45 mL. Add 5 ∗ 1 mL 10X Binding Buffer. = 50 mL 1X Binding Buffer. Procurement of valve leaflet and transportation to research laboratory Timing: 45 min Timing: 45 min In this step, we summarize our tissue collection and handling recommendations (Figure 1A).CRITICAL: Rapid processing of the sample is of critical importance to prevent unnecessary ischemia time.58.Obtain porcine heart valve leaflets.a.Euthanize the pig and perform a sternotomy.b.Locate and divide the aorta, IVC, SVC, pulmonary artery, and veins.c.Explant the heart and place in Belzer UW solution.d.Dissect the aortic and pulmonary roots using sterile scissors.e.With a #10 blade detach the aortic and pulmonary leaflets from the vessel wall. Make sure to get all the edges of the valve leaflet without including vessel tissue (Figures 2A and 2B).Figure 2Representative images of key steps in semilunar valve dissection and tissue processing(A) Initial exposure of pulmonary and aortic valves following heart explant. Use tissue forceps to gently lift the valve leaflets.(B) Fine dissection of the valve leaflets using forceps and metzebaum scissors.(C) Sectioning of valve leaflets into smaller 4-5 fragments using #10 Blade Surgical scalpel, to facilitate enzymatic digestion.(D) Tissue fragments are transferred to Eppendorf tubes containing Digest solution.(E) Enzymatic digestion is carried out in an incubator at 37 C for 2 hours with gentle agitation using Tube Revolver Rotator.(F) Post-digestion the tissue suspension is filtered through 70 μM cell strainers and homogenized using a syringe plunger.f.Take the isolated valve leaflet and place it in a labeled 15 mL tube containing PBS solution.g.Place the tissue in an ice bath and transport it to the lab for further processing.CRITICAL: When separating the leaflets, avoid as much RBC contamination as possible.CRITICAL: Work quickly and keep samples in Belzer UW solution continuously as you harvest all tissues.Figure 1Schematic overview of semilunar valve isolation, tissue processing, and flow cytometry staining(A) Procurement of semilunar valves, (B) Tissue processing and enzymatic digestion, (C) Antibody staining, (D) Annexin and viability staining. CRITICAL: Rapid processing of the sample is of critical importance to prevent unnecessary ischemia time.5 8.Obtain porcine heart valve leaflets.a.Euthanize the pig and perform a sternotomy.b.Locate and divide the aorta, IVC, SVC, pulmonary artery, and veins.c.Explant the heart and place in Belzer UW solution.d.Dissect the aortic and pulmonary roots using sterile scissors.e.With a #10 blade detach the aortic and pulmonary leaflets from the vessel wall. Make sure to get all the edges of the valve leaflet without including vessel tissue (Figures 2A and 2B).Figure 2Representative images of key steps in semilunar valve dissection and tissue processing(A) Initial exposure of pulmonary and aortic valves following heart explant. Use tissue forceps to gently lift the valve leaflets.(B) Fine dissection of the valve leaflets using forceps and metzebaum scissors.(C) Sectioning of valve leaflets into smaller 4-5 fragments using #10 Blade Surgical scalpel, to facilitate enzymatic digestion.(D) Tissue fragments are transferred to Eppendorf tubes containing Digest solution.(E) Enzymatic digestion is carried out in an incubator at 37 C for 2 hours with gentle agitation using Tube Revolver Rotator.(F) Post-digestion the tissue suspension is filtered through 70 μM cell strainers and homogenized using a syringe plunger.f.Take the isolated valve leaflet and place it in a labeled 15 mL tube containing PBS solution.g.Place the tissue in an ice bath and transport it to the lab for further processing. Obtain porcine heart valve leaflets.a.Euthanize the pig and perform a sternotomy.b.Locate and divide the aorta, IVC, SVC, pulmonary artery, and veins.c.Explant the heart and place in Belzer UW solution.d.Dissect the aortic and pulmonary roots using sterile scissors.e.With a #10 blade detach the aortic and pulmonary leaflets from the vessel wall. Make sure to get all the edges of the valve leaflet without including vessel tissue (Figures 2A and 2B).Figure 2Representative images of key steps in semilunar valve dissection and tissue processing(A) Initial exposure of pulmonary and aortic valves following heart explant. Use tissue forceps to gently lift the valve leaflets.(B) Fine dissection of the valve leaflets using forceps and metzebaum scissors.(C) Sectioning of valve leaflets into smaller 4-5 fragments using #10 Blade Surgical scalpel, to facilitate enzymatic digestion.(D) Tissue fragments are transferred to Eppendorf tubes containing Digest solution.(E) Enzymatic digestion is carried out in an incubator at 37 C for 2 hours with gentle agitation using Tube Revolver Rotator.(F) Post-digestion the tissue suspension is filtered through 70 μM cell strainers and homogenized using a syringe plunger.f.Take the isolated valve leaflet and place it in a labeled 15 mL tube containing PBS solution.g.Place the tissue in an ice bath and transport it to the lab for further processing. a.Euthanize the pig and perform a sternotomy. Euthanize the pig and perform a sternotomy. b.Locate and divide the aorta, IVC, SVC, pulmonary artery, and veins. Locate and divide the aorta, IVC, SVC, pulmonary artery, and veins. c.Explant the heart and place in Belzer UW solution. Explant the heart and place in Belzer UW solution. d.Dissect the aortic and pulmonary roots using sterile scissors. Dissect the aortic and pulmonary roots using sterile scissors. e.With a #10 blade detach the aortic and pulmonary leaflets from the vessel wall. Make sure to get all the edges of the valve leaflet without including vessel tissue (Figures 2A and 2B).Figure 2Representative images of key steps in semilunar valve dissection and tissue processing(A) Initial exposure of pulmonary and aortic valves following heart explant. Use tissue forceps to gently lift the valve leaflets.(B) Fine dissection of the valve leaflets using forceps and metzebaum scissors.(C) Sectioning of valve leaflets into smaller 4-5 fragments using #10 Blade Surgical scalpel, to facilitate enzymatic digestion.(D) Tissue fragments are transferred to Eppendorf tubes containing Digest solution.(E) Enzymatic digestion is carried out in an incubator at 37 C for 2 hours with gentle agitation using Tube Revolver Rotator.(F) Post-digestion the tissue suspension is filtered through 70 μM cell strainers and homogenized using a syringe plunger. With a #10 blade detach the aortic and pulmonary leaflets from the vessel wall. Make sure to get all the edges of the valve leaflet without including vessel tissue (Figures 2A and 2B).Figure 2Representative images of key steps in semilunar valve dissection and tissue processing(A) Initial exposure of pulmonary and aortic valves following heart explant. Use tissue forceps to gently lift the valve leaflets.(B) Fine dissection of the valve leaflets using forceps and metzebaum scissors.(C) Sectioning of valve leaflets into smaller 4-5 fragments using #10 Blade Surgical scalpel, to facilitate enzymatic digestion.(D) Tissue fragments are transferred to Eppendorf tubes containing Digest solution.(E) Enzymatic digestion is carried out in an incubator at 37 C for 2 hours with gentle agitation using Tube Revolver Rotator.(F) Post-digestion the tissue suspension is filtered through 70 μM cell strainers and homogenized using a syringe plunger. Representative images of key steps in semilunar valve dissection and tissue processing (A) Initial exposure of pulmonary and aortic valves following heart explant. Use tissue forceps to gently lift the valve leaflets. (B) Fine dissection of the valve leaflets using forceps and metzebaum scissors. (C) Sectioning of valve leaflets into smaller 4-5 fragments using #10 Blade Surgical scalpel, to facilitate enzymatic digestion. (D) Tissue fragments are transferred to Eppendorf tubes containing Digest solution. (E) Enzymatic digestion is carried out in an incubator at 37 C for 2 hours with gentle agitation using Tube Revolver Rotator. (F) Post-digestion the tissue suspension is filtered through 70 μM cell strainers and homogenized using a syringe plunger. f.Take the isolated valve leaflet and place it in a labeled 15 mL tube containing PBS solution. Take the isolated valve leaflet and place it in a labeled 15 mL tube containing PBS solution. g.Place the tissue in an ice bath and transport it to the lab for further processing. Place the tissue in an ice bath and transport it to the lab for further processing. CRITICAL: When separating the leaflets, avoid as much RBC contamination as possible. CRITICAL: Work quickly and keep samples in Belzer UW solution continuously as you harvest all tissues. Schematic overview of semilunar valve isolation, tissue processing, and flow cytometry staining (A) Procurement of semilunar valves, (B) Tissue processing and enzymatic digestion, (C) Antibody staining, (D) Annexin and viability staining. Tissue processing and digestion Timing: 3 h Timing: 3 h This section describes the procedure for processing and digesting valvular tissues to prepare them for further analysis (Figure 1B).9.Digest the valvular tissue for cell isolation.a.Remove each leaflet tissue from the 15 mL tube and place it in their respective labeled petri dish.b.Dice up the leaflets in 5 slices using a #10 blade until pieces are approximately 0.5 mm in length (Figure 2C).c.Immediately after, transfer the leaflet slices into labeled Eppendorf 1.5 mL tubes containing 1 mL Digest solution (Figure 2D).d.Transfer them to a 37 C incubator for 2 hours while gently agitating the sample using a Tube Revolver Rotator at 25 rpm (Figure 2E).Note: Processing time may vary depending on the size of the leaflet. In general, larger, fibrosed valve leaflets may need additional time for proper dissociation, while smaller, less dense ones tend to dissociate more quickly. However, longer incubation increases the risk of damaging the endothelial cells on the surface of the valve leaflet. Therefore, the incubation time should be optimized to find a balance that allows proper digestion while preserving endothelial integrity for flow cytometry evaluation. Our group experimented with different incubation time points from 5 min to 2.5 hours. We recommend using a minimum digestion time of 1.5 hours, with an ideal incubation time of 2 hours for optimal digestion and viability (Figure 3). 9.Digest the valvular tissue for cell isolation.a.Remove each leaflet tissue from the 15 mL tube and place it in their respective labeled petri dish.b.Dice up the leaflets in 5 slices using a #10 blade until pieces are approximately 0.5 mm in length (Figure 2C).c.Immediately after, transfer the leaflet slices into labeled Eppendorf 1.5 mL tubes containing 1 mL Digest solution (Figure 2D).d.Transfer them to a 37 C incubator for 2 hours while gently agitating the sample using a Tube Revolver Rotator at 25 rpm (Figure 2E). Digest the valvular tissue for cell isolation.a.Remove each leaflet tissue from the 15 mL tube and place it in their respective labeled petri dish.b.Dice up the leaflets in 5 slices using a #10 blade until pieces are approximately 0.5 mm in length (Figure 2C).c.Immediately after, transfer the leaflet slices into labeled Eppendorf 1.5 mL tubes containing 1 mL Digest solution (Figure 2D).d.Transfer them to a 37 C incubator for 2 hours while gently agitating the sample using a Tube Revolver Rotator at 25 rpm (Figure 2E). a.Remove each leaflet tissue from the 15 mL tube and place it in their respective labeled petri dish. Remove each leaflet tissue from the 15 mL tube and place it in their respective labeled petri dish. b.Dice up the leaflets in 5 slices using a #10 blade until pieces are approximately 0.5 mm in length (Figure 2C). Dice up the leaflets in 5 slices using a #10 blade until pieces are approximately 0.5 mm in length (Figure 2C). c.Immediately after, transfer the leaflet slices into labeled Eppendorf 1.5 mL tubes containing 1 mL Digest solution (Figure 2D). Immediately after, transfer the leaflet slices into labeled Eppendorf 1.5 mL tubes containing 1 mL Digest solution (Figure 2D). d.Transfer them to a 37 C incubator for 2 hours while gently agitating the sample using a Tube Revolver Rotator at 25 rpm (Figure 2E). Transfer them to a 37 C incubator for 2 hours while gently agitating the sample using a Tube Revolver Rotator at 25 rpm (Figure 2E). Note: Processing time may vary depending on the size of the leaflet. In general, larger, fibrosed valve leaflets may need additional time for proper dissociation, while smaller, less dense ones tend to dissociate more quickly. However, longer incubation increases the risk of damaging the endothelial cells on the surface of the valve leaflet. Therefore, the incubation time should be optimized to find a balance that allows proper digestion while preserving endothelial integrity for flow cytometry evaluation. Our group experimented with different incubation time points from 5 min to 2.5 hours. We recommend using a minimum digestion time of 1.5 hours, with an ideal incubation time of 2 hours for optimal digestion and viability (Figure 3). 10.Homogenize tissue through a filter (Figure 2F).a.Place a sterile 70 μm cell strainer atop a pre-labeled empty 50 mL sterile conical tube.b.Transfer the entire digested tissue suspension, including both supernatant and residual fragments on the filter using a pipette.c.Use a sterile syringe plunger to gently apply pressure in circular motion to mechanically dissociate any remaining clumped tissue bits on the strainer mesh. Excessive force should be avoided to preserve cell membrane integrity and viability.d.Rinse the strainer, syringe plunger, and original digestion Eppendorf tube with 5 mL cold flow cytometry buffer solution. Pass the rinse through the same strainer to ensure maximum cell recovery. Note: Make sure to pipette the solution from the edges of the filter inferiorly. CRITICAL: Ensure all 15 mL tubes are standardized to equal volumes before centrifugation to maintain rotor balance and experimental consistency. Adjust volumes with a Flow Buffer solution if necessary, ensuring uniformity in processing across samples 11.Centrifuge for 7 min at 400 × g at 4°C.12.Discard the supernatant.13.Resuspend the pellet in a 1000 μL flow buffer solution and transfer to 1.5 ml tubes.14.Centrifuge for 7 min at 400 × g at 4°C.15.Discard the supernatant.16.Resuspend the pellet in an 800 μL flow buffer solution.17.Pipette 5 μL of the solution in a labeled Eppendorf tube for total cell count.18.Centrifuge for 7 min at 400 × g at 4°C.19.Discard the supernatant.20.Resuspend the pellet in the appropriate volume of flow buffer solution. Note: The amount of flow buffer solution depends on the number of tests being performed to allow for 100 μL of sample for each test group. 21.Prepare 2 pre-labeled 96-well plates.a.Plate A – Antibody staining: reserve wells for samples, unstained controls, FMO controls, and compensation beads.b.Plate B – Annexin/Viability staining - reserve wells for parallel Annexin/7-AAD (or PI) staining of the same samples, processed separately. CRITICAL: Do not reuse wells from Plate A for Plate B. Process each sample in corresponding wells across both plates (e.g., Sample 1 - A1 for antibody staining, B1 for Annexin/viability staining) to ensure consistency, prevent cross-contamination, and maintain accurate fluorescence readouts. If performing only one type of staining (antibody or Annexin/viability), a single plate setup is sufficient. Figure 3Optimization of digestion time for semilunar valve cell viability in GFP and Wild-type (non-GFP) samplesSemilunar valves from GFP and wild-type (WT) pigs were digested with Collagenase P containing digest solution for 5 min, 30 min, 1 h, 1.5 h, 2 h, or 2.5 h. Following digestion, cell viability was assessed using 7-AAD staining. Histogram overlays show 7-AAD fluorescence intensity, with region R1 indicating 7-AAD–positive (non-viable) events. Comparison across conditions demonstrated that 1.5 h of digestion yielded the highest viable cell recovery and was therefore selected as the optimal incubation time. 10.Homogenize tissue through a filter (Figure 2F).a.Place a sterile 70 μm cell strainer atop a pre-labeled empty 50 mL sterile conical tube.b.Transfer the entire digested tissue suspension, including both supernatant and residual fragments on the filter using a pipette.c.Use a sterile syringe plunger to gently apply pressure in circular motion to mechanically dissociate any remaining clumped tissue bits on the strainer mesh. Excessive force should be avoided to preserve cell membrane integrity and viability.d.Rinse the strainer, syringe plunger, and original digestion Eppendorf tube with 5 mL cold flow cytometry buffer solution. Pass the rinse through the same strainer to ensure maximum cell recovery. Homogenize tissue through a filter (Figure 2F).a.Place a sterile 70 μm cell strainer atop a pre-labeled empty 50 mL sterile conical tube.b.Transfer the entire digested tissue suspension, including both supernatant and residual fragments on the filter using a pipette.c.Use a sterile syringe plunger to gently apply pressure in circular motion to mechanically dissociate any remaining clumped tissue bits on the strainer mesh. Excessive force should be avoided to preserve cell membrane integrity and viability.d.Rinse the strainer, syringe plunger, and original digestion Eppendorf tube with 5 mL cold flow cytometry buffer solution. Pass the rinse through the same strainer to ensure maximum cell recovery. a.Place a sterile 70 μm cell strainer atop a pre-labeled empty 50 mL sterile conical tube. Place a sterile 70 μm cell strainer atop a pre-labeled empty 50 mL sterile conical tube. b.Transfer the entire digested tissue suspension, including both supernatant and residual fragments on the filter using a pipette. Transfer the entire digested tissue suspension, including both supernatant and residual fragments on the filter using a pipette. c.Use a sterile syringe plunger to gently apply pressure in circular motion to mechanically dissociate any remaining clumped tissue bits on the strainer mesh. Excessive force should be avoided to preserve cell membrane integrity and viability. Use a sterile syringe plunger to gently apply pressure in circular motion to mechanically dissociate any remaining clumped tissue bits on the strainer mesh. Excessive force should be avoided to preserve cell membrane integrity and viability. d.Rinse the strainer, syringe plunger, and original digestion Eppendorf tube with 5 mL cold flow cytometry buffer solution. Pass the rinse through the same strainer to ensure maximum cell recovery. Rinse the strainer, syringe plunger, and original digestion Eppendorf tube with 5 mL cold flow cytometry buffer solution. Pass the rinse through the same strainer to ensure maximum cell recovery. Note: Make sure to pipette the solution from the edges of the filter inferiorly. CRITICAL: Ensure all 15 mL tubes are standardized to equal volumes before centrifugation to maintain rotor balance and experimental consistency. Adjust volumes with a Flow Buffer solution if necessary, ensuring uniformity in processing across samples 11.Centrifuge for 7 min at 400 × g at 4°C. Centrifuge for 7 min at 400 × g at 4°C. 12.Discard the supernatant. Discard the supernatant. 13.Resuspend the pellet in a 1000 μL flow buffer solution and transfer to 1.5 ml tubes. Resuspend the pellet in a 1000 μL flow buffer solution and transfer to 1.5 ml tubes. 14.Centrifuge for 7 min at 400 × g at 4°C. Centrifuge for 7 min at 400 × g at 4°C. 15.Discard the supernatant. Discard the supernatant. 16.Resuspend the pellet in an 800 μL flow buffer solution. Resuspend the pellet in an 800 μL flow buffer solution. 17.Pipette 5 μL of the solution in a labeled Eppendorf tube for total cell count. Pipette 5 μL of the solution in a labeled Eppendorf tube for total cell count. 18.Centrifuge for 7 min at 400 × g at 4°C. Centrifuge for 7 min at 400 × g at 4°C. 19.Discard the supernatant. Discard the supernatant. 20.Resuspend the pellet in the appropriate volume of flow buffer solution. Resuspend the pellet in the appropriate volume of flow buffer solution. Note: The amount of flow buffer solution depends on the number of tests being performed to allow for 100 μL of sample for each test group. 21.Prepare 2 pre-labeled 96-well plates.a.Plate A – Antibody staining: reserve wells for samples, unstained controls, FMO controls, and compensation beads.b.Plate B – Annexin/Viability staining - reserve wells for parallel Annexin/7-AAD (or PI) staining of the same samples, processed separately. Prepare 2 pre-labeled 96-well plates.a.Plate A – Antibody staining: reserve wells for samples, unstained controls, FMO controls, and compensation beads.b.Plate B – Annexin/Viability staining - reserve wells for parallel Annexin/7-AAD (or PI) staining of the same samples, processed separately. a.Plate A – Antibody staining: reserve wells for samples, unstained controls, FMO controls, and compensation beads. Plate A – Antibody staining: reserve wells for samples, unstained controls, FMO controls, and compensation beads. b.Plate B – Annexin/Viability staining - reserve wells for parallel Annexin/7-AAD (or PI) staining of the same samples, processed separately. Plate B – Annexin/Viability staining - reserve wells for parallel Annexin/7-AAD (or PI) staining of the same samples, processed separately. CRITICAL: Do not reuse wells from Plate A for Plate B. Process each sample in corresponding wells across both plates (e.g., Sample 1 - A1 for antibody staining, B1 for Annexin/viability staining) to ensure consistency, prevent cross-contamination, and maintain accurate fluorescence readouts. If performing only one type of staining (antibody or Annexin/viability), a single plate setup is sufficient. Optimization of digestion time for semilunar valve cell viability in GFP and Wild-type (non-GFP) samples Semilunar valves from GFP and wild-type (WT) pigs were digested with Collagenase P containing digest solution for 5 min, 30 min, 1 h, 1.5 h, 2 h, or 2.5 h. Following digestion, cell viability was assessed using 7-AAD staining. Histogram overlays show 7-AAD fluorescence intensity, with region R1 indicating 7-AAD–positive (non-viable) events. Comparison across conditions demonstrated that 1.5 h of digestion yielded the highest viable cell recovery and was therefore selected as the optimal incubation time. Antibody staining of samples Timing: 1 h Timing: 1 h This section outlines the procedure for staining isolated cells with antibodies, allowing for the identification of specific cell populations via flow cytometry. For optimal analysis of your flow cytometry data, we recommend preparing FMO and unstained controls (Figure 1C).CRITICAL: All steps are performed at 4°C to prevent endocytosis of surface antigens, reduce non-specific binding, and minimize antibody-induced activation. This ensures accurate surface staining and preserves native cell states.22.Aliquot 100 μL of sample into each well of a pre-labeled 96-well plate (Plate A).23.Add compensation beads to the appropriate wells.24.Centrifuge for 7 min at 400 × g in RT at 4°C.25.Discard the supernatant.26.Resuspend the pellet in a 100 μL flow buffer solution.27.Add 2 μL/sample BD anti-Hu Fc Receptor block in CD3 and CD31 labeled wells.28.Add antibody volume to cells in marked wells as labeled.a.anti-Pig CD31 - 10 μL of the suggested working dilution to label 100 μL sample.b.anti-Pig CD3 - 5 μL of the suggested working dilution to label 100 μL sample.c.Mix gently by pipetting up and down 5–10 times.d.Incubate cells and antibodies with the lid placed on a 96-well plate, for 30 min in the dark at 4°C on incubating microplate shaker.e.Centrifuge for 7 min at 400 × g at 4°C.Note: Use an empty 96-well plate with a lid to counterbalance the centrifuge.f.Discard the supernatant in one firm movement.g.Resuspend the pellet in 200 μL of flow buffer solution.29.Add viability staining solution to the marked cells.a.Add 10 μL Propidium iodide or 10 μL 7-AAD to each 200 μL sample.b.Incubate cells with the lid placed on 96-well plate for 5–10 minutes in the dark at 4°C on incubating microplate shaker.30.The sample is ready for flow cytometry, measure the cells immediately. CRITICAL: All steps are performed at 4°C to prevent endocytosis of surface antigens, reduce non-specific binding, and minimize antibody-induced activation. This ensures accurate surface staining and preserves native cell states. 22.Aliquot 100 μL of sample into each well of a pre-labeled 96-well plate (Plate A). Aliquot 100 μL of sample into each well of a pre-labeled 96-well plate (Plate A). 23.Add compensation beads to the appropriate wells. Add compensation beads to the appropriate wells. 24.Centrifuge for 7 min at 400 × g in RT at 4°C. Centrifuge for 7 min at 400 × g in RT at 4°C. 25.Discard the supernatant. Discard the supernatant. 26.Resuspend the pellet in a 100 μL flow buffer solution. Resuspend the pellet in a 100 μL flow buffer solution. 27.Add 2 μL/sample BD anti-Hu Fc Receptor block in CD3 and CD31 labeled wells. Add 2 μL/sample BD anti-Hu Fc Receptor block in CD3 and CD31 labeled wells. 28.Add antibody volume to cells in marked wells as labeled.a.anti-Pig CD31 - 10 μL of the suggested working dilution to label 100 μL sample.b.anti-Pig CD3 - 5 μL of the suggested working dilution to label 100 μL sample.c.Mix gently by pipetting up and down 5–10 times.d.Incubate cells and antibodies with the lid placed on a 96-well plate, for 30 min in the dark at 4°C on incubating microplate shaker.e.Centrifuge for 7 min at 400 × g at 4°C.Note: Use an empty 96-well plate with a lid to counterbalance the centrifuge.f.Discard the supernatant in one firm movement.g.Resuspend the pellet in 200 μL of flow buffer solution. Add antibody volume to cells in marked wells as labeled.a.anti-Pig CD31 - 10 μL of the suggested working dilution to label 100 μL sample.b.anti-Pig CD3 - 5 μL of the suggested working dilution to label 100 μL sample.c.Mix gently by pipetting up and down 5–10 times.d.Incubate cells and antibodies with the lid placed on a 96-well plate, for 30 min in the dark at 4°C on incubating microplate shaker.e.Centrifuge for 7 min at 400 × g at 4°C.Note: Use an empty 96-well plate with a lid to counterbalance the centrifuge.f.Discard the supernatant in one firm movement.g.Resuspend the pellet in 200 μL of flow buffer solution. a.anti-Pig CD31 - 10 μL of the suggested working dilution to label 100 μL sample. anti-Pig CD31 - 10 μL of the suggested working dilution to label 100 μL sample. b.anti-Pig CD3 - 5 μL of the suggested working dilution to label 100 μL sample. anti-Pig CD3 - 5 μL of the suggested working dilution to label 100 μL sample. c.Mix gently by pipetting up and down 5–10 times. Mix gently by pipetting up and down 5–10 times. d.Incubate cells and antibodies with the lid placed on a 96-well plate, for 30 min in the dark at 4°C on incubating microplate shaker. Incubate cells and antibodies with the lid placed on a 96-well plate, for 30 min in the dark at 4°C on incubating microplate shaker. e.Centrifuge for 7 min at 400 × g at 4°C.Note: Use an empty 96-well plate with a lid to counterbalance the centrifuge. Centrifuge for 7 min at 400 × g at 4°C.Note: Use an empty 96-well plate with a lid to counterbalance the centrifuge. Note: Use an empty 96-well plate with a lid to counterbalance the centrifuge. f.Discard the supernatant in one firm movement. Discard the supernatant in one firm movement. g.Resuspend the pellet in 200 μL of flow buffer solution. Resuspend the pellet in 200 μL of flow buffer solution. 29.Add viability staining solution to the marked cells.a.Add 10 μL Propidium iodide or 10 μL 7-AAD to each 200 μL sample.b.Incubate cells with the lid placed on 96-well plate for 5–10 minutes in the dark at 4°C on incubating microplate shaker. Add viability staining solution to the marked cells.a.Add 10 μL Propidium iodide or 10 μL 7-AAD to each 200 μL sample.b.Incubate cells with the lid placed on 96-well plate for 5–10 minutes in the dark at 4°C on incubating microplate shaker. a.Add 10 μL Propidium iodide or 10 μL 7-AAD to each 200 μL sample. Add 10 μL Propidium iodide or 10 μL 7-AAD to each 200 μL sample. b.Incubate cells with the lid placed on 96-well plate for 5–10 minutes in the dark at 4°C on incubating microplate shaker. Incubate cells with the lid placed on 96-well plate for 5–10 minutes in the dark at 4°C on incubating microplate shaker. 30.The sample is ready for flow cytometry, measure the cells immediately. The sample is ready for flow cytometry, measure the cells immediately. Annexin and viability staining of samples Timing: 1 h Timing: 1 h This section outlines the procedure for staining the isolated cells with viability and apoptotic stain, allowing for the identification of healthy cell populations via flow cytometry (Figure 1D).31.Aliquot 100 μL of sample into each well of a pre-labeled 96-well plate (Plate B).32.Centrifuge for 7 min at 400 × g in RT at 4°C.33.Discard the supernatant.34.Wash all wells with PBS.a.Resuspend the pellet in 200 μL PBS.b.Mix by pipetting up and down 10 times.c.Centrifuge for 3 min at 400 × g at 4°C.d.Discard the supernatant in one firm movement.35.Wash all wells with 1X Binding Buffer.a.Resuspend the pellet in 200 μL 1X Binding Buffer.b.Mix by pipetting up and down 10 times.c.Centrifuge for 3 min at 400 × g at 4°C.d.Discard the supernatant in one firm movement.36.Resuspend cells in 1 mL 1X Binding Buffer.37.Add 5 μL of fluorochrome-conjugated Annexin V to 100 μL of the cell suspension.a.Incubate sample with the lid placed on a 96-well plate, for 15 min in the dark at 20°C–25°C.b.Centrifuge for 7 min at 400 × g at 4°C.c.Discard the supernatant in one firm movement.38.Wash cells in 1X Binding Buffer.a.Resuspend the pellet in 100 μL 1X Binding Buffer.b.Mix by pipetting up and down 10 times.c.Centrifuge for 7 min at 400 × g at 4°C.39.Discard the supernatant in one firm movement.40.Resuspend cells in 200 μL of 1X Binding Buffer.41.Add 5 μL of 7-AAD Viability Staining Solution.a.Incubate sample with the lid placed on a 96-well plate, on incubating microplate shaker for 5 min in the dark at 4°C.42.The sample is ready for flow cytometry, measure the cells immediately. 31.Aliquot 100 μL of sample into each well of a pre-labeled 96-well plate (Plate B). Aliquot 100 μL of sample into each well of a pre-labeled 96-well plate (Plate B). 32.Centrifuge for 7 min at 400 × g in RT at 4°C. Centrifuge for 7 min at 400 × g in RT at 4°C. 33.Discard the supernatant. Discard the supernatant. 34.Wash all wells with PBS.a.Resuspend the pellet in 200 μL PBS.b.Mix by pipetting up and down 10 times.c.Centrifuge for 3 min at 400 × g at 4°C.d.Discard the supernatant in one firm movement. Wash all wells with PBS.a.Resuspend the pellet in 200 μL PBS.b.Mix by pipetting up and down 10 times.c.Centrifuge for 3 min at 400 × g at 4°C.d.Discard the supernatant in one firm movement. a.Resuspend the pellet in 200 μL PBS. Resuspend the pellet in 200 μL PBS. b.Mix by pipetting up and down 10 times. Mix by pipetting up and down 10 times. c.Centrifuge for 3 min at 400 × g at 4°C. Centrifuge for 3 min at 400 × g at 4°C. d.Discard the supernatant in one firm movement. Discard the supernatant in one firm movement. 35.Wash all wells with 1X Binding Buffer.a.Resuspend the pellet in 200 μL 1X Binding Buffer.b.Mix by pipetting up and down 10 times.c.Centrifuge for 3 min at 400 × g at 4°C.d.Discard the supernatant in one firm movement. Wash all wells with 1X Binding Buffer.a.Resuspend the pellet in 200 μL 1X Binding Buffer.b.Mix by pipetting up and down 10 times.c.Centrifuge for 3 min at 400 × g at 4°C.d.Discard the supernatant in one firm movement. a.Resuspend the pellet in 200 μL 1X Binding Buffer. Resuspend the pellet in 200 μL 1X Binding Buffer. b.Mix by pipetting up and down 10 times. Mix by pipetting up and down 10 times. c.Centrifuge for 3 min at 400 × g at 4°C. Centrifuge for 3 min at 400 × g at 4°C. d.Discard the supernatant in one firm movement. Discard the supernatant in one firm movement. 36.Resuspend cells in 1 mL 1X Binding Buffer. Resuspend cells in 1 mL 1X Binding Buffer. 37.Add 5 μL of fluorochrome-conjugated Annexin V to 100 μL of the cell suspension.a.Incubate sample with the lid placed on a 96-well plate, for 15 min in the dark at 20°C–25°C.b.Centrifuge for 7 min at 400 × g at 4°C.c.Discard the supernatant in one firm movement. Add 5 μL of fluorochrome-conjugated Annexin V to 100 μL of the cell suspension.a.Incubate sample with the lid placed on a 96-well plate, for 15 min in the dark at 20°C–25°C.b.Centrifuge for 7 min at 400 × g at 4°C.c.Discard the supernatant in one firm movement. a.Incubate sample with the lid placed on a 96-well plate, for 15 min in the dark at 20°C–25°C. Incubate sample with the lid placed on a 96-well plate, for 15 min in the dark at 20°C–25°C. b.Centrifuge for 7 min at 400 × g at 4°C. Centrifuge for 7 min at 400 × g at 4°C. c.Discard the supernatant in one firm movement. Discard the supernatant in one firm movement. 38.Wash cells in 1X Binding Buffer.a.Resuspend the pellet in 100 μL 1X Binding Buffer.b.Mix by pipetting up and down 10 times.c.Centrifuge for 7 min at 400 × g at 4°C. Wash cells in 1X Binding Buffer.a.Resuspend the pellet in 100 μL 1X Binding Buffer.b.Mix by pipetting up and down 10 times.c.Centrifuge for 7 min at 400 × g at 4°C. a.Resuspend the pellet in 100 μL 1X Binding Buffer. Resuspend the pellet in 100 μL 1X Binding Buffer. b.Mix by pipetting up and down 10 times. Mix by pipetting up and down 10 times. c.Centrifuge for 7 min at 400 × g at 4°C. Centrifuge for 7 min at 400 × g at 4°C. 39.Discard the supernatant in one firm movement. Discard the supernatant in one firm movement. 40.Resuspend cells in 200 μL of 1X Binding Buffer. Resuspend cells in 200 μL of 1X Binding Buffer. 41.Add 5 μL of 7-AAD Viability Staining Solution.a.Incubate sample with the lid placed on a 96-well plate, on incubating microplate shaker for 5 min in the dark at 4°C. Add 5 μL of 7-AAD Viability Staining Solution.a.Incubate sample with the lid placed on a 96-well plate, on incubating microplate shaker for 5 min in the dark at 4°C. a.Incubate sample with the lid placed on a 96-well plate, on incubating microplate shaker for 5 min in the dark at 4°C. Incubate sample with the lid placed on a 96-well plate, on incubating microplate shaker for 5 min in the dark at 4°C. 42.The sample is ready for flow cytometry, measure the cells immediately. The sample is ready for flow cytometry, measure the cells immediately. Sample acquisition Timing: 15 min Timing: 15 min This step describes how to acquire single-cell suspension with the Flow Cytometer efficiently.43.Load the stained 96-well plate into the autosampler chamber.44.Validate the target population and record it in the acquisition template.CRITICAL: Program the flow cytometer to run half of the each sample (accounting for the 30 μL dead volume per 100 μL acquisition) to maximize data collection while reserving the other half for a contingency like instrument failure.Note: Avoid cell aggregates by ensuring proper sample preparation and resuspension before acquisition. Aggregates can distort fluorescence intensity and population percentages, reducing the accuracy and reproducibility of single-cell analysis. 43.Load the stained 96-well plate into the autosampler chamber. Load the stained 96-well plate into the autosampler chamber. 44.Validate the target population and record it in the acquisition template. Validate the target population and record it in the acquisition template. CRITICAL: Program the flow cytometer to run half of the each sample (accounting for the 30 μL dead volume per 100 μL acquisition) to maximize data collection while reserving the other half for a contingency like instrument failure. Note: Avoid cell aggregates by ensuring proper sample preparation and resuspension before acquisition. Aggregates can distort fluorescence intensity and population percentages, reducing the accuracy and reproducibility of single-cell analysis. Gating strategy for analysis Timing: 20 min Timing: 20 min This section outlines the procedures for gating the acquired data, ensuring accurate identification and analysis of each cell type (Figures 4 and 5).45.R1: Single-Cell Selection.a.Use a Forward Scatter Area (FSC-A) vs. Forward Scatter Height (FSC-H) plot to select single cells.Note: Gate on the single-cell population. In the plot, single cells will align along a diagonal line, while doublets and aggregates will deviate from this line.46.R2: Debris Exclusion.a.Use forward scatter (FSC-H) and side scatter (SSC-A) to identify live cells and exclude debris and dead cells within the single-cell population (R1-gated).47.R3: Viability Confirmation.a.Assess cellular viability within the R2-gated population using a viability dye (e.g., 7-AAD or propidium iodide).48.Subpopulation Identification.a.R4: Endothelial cells.i.Identify CD31+ cells within the viable population (R3-gated).b.R5: T cells.i.Detect CD3+ T lymphocytes within the viable population (R3-gated).c.R6: GFP+ Cells.i.Analyze GFP-positive cells within the viable population (R3-gated).49.Apoptotic cell identification (Figure 6).Figure 6Sequential gating strategy for viability and apoptosis analysis of pulmonary and aortic semilunar valves(A1-A2) Singlet selection (R1): FSC-H versus FSC-A plots were used to identify singlets and exclude doublets or aggregates.(B1-B2) Live cell population gating (R2): From the singlet gate, debris, highly granular events, and noise were excluded in FSC-H versus SSC-H plots to isolate the main viable cell population.(C1-C2) Apoptosis and viability assessment (R3): Cells within the R2 gate were analyzed using Annexin V and 7-AAD staining to distinguish live (Annexin V-/7-AAD-), early apoptotic (Annexin V+/7-AAD-), late apoptotic (Annexin V+/7-AAD+), and dead (Annexin V-/7-AAD+) cells.50.Using the Attune Nxt Software, make scatter plots as shown Figure 7.Figure 7Scatter plot analysis using Attune Nxt Software(A) CD3 vs. CD31: Distinct CD3+/CD31- T cells and CD3-/CD31+ endothelial cells without overlap.(B) CD31 vs. GFP: Nearly all CD31+ endothelial cells are GFP+ donor-derived, with only minimal GFP-/CD31+ background signal.(C) CD3 vs. GFP (native): Predominantly GFP-/CD3- healthy valve cells with no detectable CD3+ T cells, indicating absence of baseline immune activity in non-transplanted valves.(D) CD3 vs. GFP (diseased): Robust GFP-/CD3+ recipient T cell infiltration with loss of GFP+/CD3- donor cells, consistent with acute rejection and donor cell death.Figure 4Gating strategy for analysis of isolated native Aortic valve cells(A) Single cell gating (R1): Doublets and large aggregates were excluded using FSC-H vs. FSC-A plot to isolate single cells.(B) Target cell gating (R2): From the R1-gated single-cell population, debris and highly granular events were excluded based on FSC-H vs SSC-H to define target cell populations.(C) Viability gating (R4): Live cells were selected from the R2-gated population using 7-AAD staining, excluding 7-AAD+ dead cells. Identification of viable cell subsets (R4-gated population).(D) CD31+ endothelial cells (R6): Identified by CD31 expression.(E) CD3+ T cells (R5): Identified by CD3 expression.(F) GFP+ cells (R7): Identified by GFP signal, representing donor native cells.Gating strategy for GFP+ isolated cells.(G) Single-cell gating (R1): Within GFP+ samples, single cells were selected using FSC-H versus FSC-A, excluding aggregates.(H) Viability gating (R4): Live cells were selected using 7-AAD staining to exclude dead cells.(I) Low GFP+ population: A smaller subpopulation of GFP+ cells was identified in R8-gated target population.(J) Intermediate GFP+ population: GFP+ cells with mid-level expression were identified within R2-gated target population.(K) High GFP+ population: A large subpopulation of GFP+ cells were identified within R3-gated target population.Fluorescence Minus One (FMO) controls were used to establish accurate gating thresholds for all markers.This gating strategy sequentially isolates viable single cells from native aortic valve samples, distinguishes subpopulations within healthy tissue (CD31+ endothelial, CD3+ T cells, and GFP+ cells), and further stratifies GFP+ cells into low, intermediate, and high GFP-expressing subpopulations for downstream analysis.Figure 5Gating strategy for analysis of transplanted GFP+ Pulmonary valve cells(A) Single cell gating (R1): Doublets and large events were excluded using FSC-H vs. FSC-A plot to isolate single cells.(B) Viability gating (R4): Live cells were selected from R1-gated population using 7-AAD staining, excluding dead (7-AAD+) cells.(C) Target Cell gating (R2-R3): From viable cells (R4), debris and highly granular events were excluded by FSC-H vs. SSC-H to define target populations.Identification of viable cell subsets.(D) CD31+ endothelial cells (R6): Identified by CD31 expression within R4-gated viable cell population.(E) GFP+ cells (R7): Identified by GFP signal within R4-gated viable cell population.(F) Scatter plot of donor endothelial cells: Frequency of GFP+ and CD31+ subsets within the R2-gated population after graft rejection.Analysis of CD3+ T cells within different target-gated populations.(G) CD3+ T cells (R9): Identified by CD3 expression within R2-gated population.(H) CD3+ T cells (R5): Identified by CD3 expression within R3-gated population.(I) Scatter plot of recipient T cells: Proportion of GFP-, CD3+ recipient T cells in the graft (R2-gated).(J) CD3+ T cell pre-gating (R12): Subpopulation isolated from live, R2-gated target cells.(K) CD3+ T cells (R13): Identified by CD3 expression within R12-gated population.(L) Scatter plot of CD3+ subsets: Distribution of GFP-, CD3+ recipient T cells versus GFP+, CD3- cells within the R12-gated population after rejection.Fluorescence minus one (FMO) controls were used to establish accurate gating thresholds for all markers.This gating strategy sequentially isolates viable single cells from transplanted pulmonary valve samples, distinguishes host-derived (CD3+ T cells) and donor-derived (CD31+ endothelial, GFP+ cells) populations, and further analysis recipient vs donor cells through quadrant analysis (GFP−/+, CD31−/+ or CD3−/+). In particular, CD3+ T cell subsets are progressively isolated using multiple gating steps, enabling precise identification of recipient-derived GFP-/CD3+ cells vs donor-derived GFP+/CD3- populations within the graft after rejection. 45.R1: Single-Cell Selection.a.Use a Forward Scatter Area (FSC-A) vs. Forward Scatter Height (FSC-H) plot to select single cells. R1: Single-Cell Selection.a.Use a Forward Scatter Area (FSC-A) vs. Forward Scatter Height (FSC-H) plot to select single cells. a.Use a Forward Scatter Area (FSC-A) vs. Forward Scatter Height (FSC-H) plot to select single cells. Use a Forward Scatter Area (FSC-A) vs. Forward Scatter Height (FSC-H) plot to select single cells. Note: Gate on the single-cell population. In the plot, single cells will align along a diagonal line, while doublets and aggregates will deviate from this line. 46.R2: Debris Exclusion.a.Use forward scatter (FSC-H) and side scatter (SSC-A) to identify live cells and exclude debris and dead cells within the single-cell population (R1-gated). R2: Debris Exclusion.a.Use forward scatter (FSC-H) and side scatter (SSC-A) to identify live cells and exclude debris and dead cells within the single-cell population (R1-gated). a.Use forward scatter (FSC-H) and side scatter (SSC-A) to identify live cells and exclude debris and dead cells within the single-cell population (R1-gated). Use forward scatter (FSC-H) and side scatter (SSC-A) to identify live cells and exclude debris and dead cells within the single-cell population (R1-gated). 47.R3: Viability Confirmation.a.Assess cellular viability within the R2-gated population using a viability dye (e.g., 7-AAD or propidium iodide). R3: Viability Confirmation.a.Assess cellular viability within the R2-gated population using a viability dye (e.g., 7-AAD or propidium iodide). a.Assess cellular viability within the R2-gated population using a viability dye (e.g., 7-AAD or propidium iodide). Assess cellular viability within the R2-gated population using a viability dye (e.g., 7-AAD or propidium iodide). 48.Subpopulation Identification.a.R4: Endothelial cells.i.Identify CD31+ cells within the viable population (R3-gated).b.R5: T cells.i.Detect CD3+ T lymphocytes within the viable population (R3-gated).c.R6: GFP+ Cells.i.Analyze GFP-positive cells within the viable population (R3-gated). Subpopulation Identification.a.R4: Endothelial cells.i.Identify CD31+ cells within the viable population (R3-gated).b.R5: T cells.i.Detect CD3+ T lymphocytes within the viable population (R3-gated).c.R6: GFP+ Cells.i.Analyze GFP-positive cells within the viable population (R3-gated). a.R4: Endothelial cells.i.Identify CD31+ cells within the viable population (R3-gated). R4: Endothelial cells.i.Identify CD31+ cells within the viable population (R3-gated). i.Identify CD31+ cells within the viable population (R3-gated). Identify CD31+ cells within the viable population (R3-gated). b.R5: T cells.i.Detect CD3+ T lymphocytes within the viable population (R3-gated). R5: T cells.i.Detect CD3+ T lymphocytes within the viable population (R3-gated). i.Detect CD3+ T lymphocytes within the viable population (R3-gated). Detect CD3+ T lymphocytes within the viable population (R3-gated). c.R6: GFP+ Cells.i.Analyze GFP-positive cells within the viable population (R3-gated). R6: GFP+ Cells.i.Analyze GFP-positive cells within the viable population (R3-gated). i.Analyze GFP-positive cells within the viable population (R3-gated). Analyze GFP-positive cells within the viable population (R3-gated). 49.Apoptotic cell identification (Figure 6).Figure 6Sequential gating strategy for viability and apoptosis analysis of pulmonary and aortic semilunar valves(A1-A2) Singlet selection (R1): FSC-H versus FSC-A plots were used to identify singlets and exclude doublets or aggregates.(B1-B2) Live cell population gating (R2): From the singlet gate, debris, highly granular events, and noise were excluded in FSC-H versus SSC-H plots to isolate the main viable cell population.(C1-C2) Apoptosis and viability assessment (R3): Cells within the R2 gate were analyzed using Annexin V and 7-AAD staining to distinguish live (Annexin V-/7-AAD-), early apoptotic (Annexin V+/7-AAD-), late apoptotic (Annexin V+/7-AAD+), and dead (Annexin V-/7-AAD+) cells. Apoptotic cell identification (Figure 6).Figure 6Sequential gating strategy for viability and apoptosis analysis of pulmonary and aortic semilunar valves(A1-A2) Singlet selection (R1): FSC-H versus FSC-A plots were used to identify singlets and exclude doublets or aggregates.(B1-B2) Live cell population gating (R2): From the singlet gate, debris, highly granular events, and noise were excluded in FSC-H versus SSC-H plots to isolate the main viable cell population.(C1-C2) Apoptosis and viability assessment (R3): Cells within the R2 gate were analyzed using Annexin V and 7-AAD staining to distinguish live (Annexin V-/7-AAD-), early apoptotic (Annexin V+/7-AAD-), late apoptotic (Annexin V+/7-AAD+), and dead (Annexin V-/7-AAD+) cells. Sequential gating strategy for viability and apoptosis analysis of pulmonary and aortic semilunar valves (A1-A2) Singlet selection (R1): FSC-H versus FSC-A plots were used to identify singlets and exclude doublets or aggregates. (B1-B2) Live cell population gating (R2): From the singlet gate, debris, highly granular events, and noise were excluded in FSC-H versus SSC-H plots to isolate the main viable cell population. (C1-C2) Apoptosis and viability assessment (R3): Cells within the R2 gate were analyzed using Annexin V and 7-AAD staining to distinguish live (Annexin V-/7-AAD-), early apoptotic (Annexin V+/7-AAD-), late apoptotic (Annexin V+/7-AAD+), and dead (Annexin V-/7-AAD+) cells. 50.Using the Attune Nxt Software, make scatter plots as shown Figure 7.Figure 7Scatter plot analysis using Attune Nxt Software(A) CD3 vs. CD31: Distinct CD3+/CD31- T cells and CD3-/CD31+ endothelial cells without overlap.(B) CD31 vs. GFP: Nearly all CD31+ endothelial cells are GFP+ donor-derived, with only minimal GFP-/CD31+ background signal.(C) CD3 vs. GFP (native): Predominantly GFP-/CD3- healthy valve cells with no detectable CD3+ T cells, indicating absence of baseline immune activity in non-transplanted valves.(D) CD3 vs. GFP (diseased): Robust GFP-/CD3+ recipient T cell infiltration with loss of GFP+/CD3- donor cells, consistent with acute rejection and donor cell death. Using the Attune Nxt Software, make scatter plots as shown Figure 7.Figure 7Scatter plot analysis using Attune Nxt Software(A) CD3 vs. CD31: Distinct CD3+/CD31- T cells and CD3-/CD31+ endothelial cells without overlap.(B) CD31 vs. GFP: Nearly all CD31+ endothelial cells are GFP+ donor-derived, with only minimal GFP-/CD31+ background signal.(C) CD3 vs. GFP (native): Predominantly GFP-/CD3- healthy valve cells with no detectable CD3+ T cells, indicating absence of baseline immune activity in non-transplanted valves.(D) CD3 vs. GFP (diseased): Robust GFP-/CD3+ recipient T cell infiltration with loss of GFP+/CD3- donor cells, consistent with acute rejection and donor cell death. Scatter plot analysis using Attune Nxt Software (A) CD3 vs. CD31: Distinct CD3+/CD31- T cells and CD3-/CD31+ endothelial cells without overlap. (B) CD31 vs. GFP: Nearly all CD31+ endothelial cells are GFP+ donor-derived, with only minimal GFP-/CD31+ background signal. (C) CD3 vs. GFP (native): Predominantly GFP-/CD3- healthy valve cells with no detectable CD3+ T cells, indicating absence of baseline immune activity in non-transplanted valves. (D) CD3 vs. GFP (diseased): Robust GFP-/CD3+ recipient T cell infiltration with loss of GFP+/CD3- donor cells, consistent with acute rejection and donor cell death. Gating strategy for analysis of isolated native Aortic valve cells (A) Single cell gating (R1): Doublets and large aggregates were excluded using FSC-H vs. FSC-A plot to isolate single cells. (B) Target cell gating (R2): From the R1-gated single-cell population, debris and highly granular events were excluded based on FSC-H vs SSC-H to define target cell populations. (C) Viability gating (R4): Live cells were selected from the R2-gated population using 7-AAD staining, excluding 7-AAD+ dead cells. Identification of viable cell subsets (R4-gated population). (D) CD31+ endothelial cells (R6): Identified by CD31 expression. (E) CD3+ T cells (R5): Identified by CD3 expression. (F) GFP+ cells (R7): Identified by GFP signal, representing donor native cells. Gating strategy for GFP+ isolated cells. (G) Single-cell gating (R1): Within GFP+ samples, single cells were selected using FSC-H versus FSC-A, excluding aggregates. (H) Viability gating (R4): Live cells were selected using 7-AAD staining to exclude dead cells. (I) Low GFP+ population: A smaller subpopulation of GFP+ cells was identified in R8-gated target population. (J) Intermediate GFP+ population: GFP+ cells with mid-level expression were identified within R2-gated target population. (K) High GFP+ population: A large subpopulation of GFP+ cells were identified within R3-gated target population. Fluorescence Minus One (FMO) controls were used to establish accurate gating thresholds for all markers. This gating strategy sequentially isolates viable single cells from native aortic valve samples, distinguishes subpopulations within healthy tissue (CD31+ endothelial, CD3+ T cells, and GFP+ cells), and further stratifies GFP+ cells into low, intermediate, and high GFP-expressing subpopulations for downstream analysis. Gating strategy for analysis of transplanted GFP+ Pulmonary valve cells (A) Single cell gating (R1): Doublets and large events were excluded using FSC-H vs. FSC-A plot to isolate single cells. (B) Viability gating (R4): Live cells were selected from R1-gated population using 7-AAD staining, excluding dead (7-AAD+) cells. (C) Target Cell gating (R2-R3): From viable cells (R4), debris and highly granular events were excluded by FSC-H vs. SSC-H to define target populations. Identification of viable cell subsets. (D) CD31+ endothelial cells (R6): Identified by CD31 expression within R4-gated viable cell population. (E) GFP+ cells (R7): Identified by GFP signal within R4-gated viable cell population. (F) Scatter plot of donor endothelial cells: Frequency of GFP+ and CD31+ subsets within the R2-gated population after graft rejection. Analysis of CD3+ T cells within different target-gated populations. (G) CD3+ T cells (R9): Identified by CD3 expression within R2-gated population. (H) CD3+ T cells (R5): Identified by CD3 expression within R3-gated population. (I) Scatter plot of recipient T cells: Proportion of GFP-, CD3+ recipient T cells in the graft (R2-gated). (J) CD3+ T cell pre-gating (R12): Subpopulation isolated from live, R2-gated target cells. (K) CD3+ T cells (R13): Identified by CD3 expression within R12-gated population. (L) Scatter plot of CD3+ subsets: Distribution of GFP-, CD3+ recipient T cells versus GFP+, CD3- cells within the R12-gated population after rejection. Fluorescence minus one (FMO) controls were used to establish accurate gating thresholds for all markers. This gating strategy sequentially isolates viable single cells from transplanted pulmonary valve samples, distinguishes host-derived (CD3+ T cells) and donor-derived (CD31+ endothelial, GFP+ cells) populations, and further analysis recipient vs donor cells through quadrant analysis (GFP−/+, CD31−/+ or CD3−/+). In particular, CD3+ T cell subsets are progressively isolated using multiple gating steps, enabling precise identification of recipient-derived GFP-/CD3+ cells vs donor-derived GFP+/CD3- populations within the graft after rejection. Expected outcomes In this protocol, we have refined existing flow cytometry techniques for our application in porcine semilunar valves. Single-cell suspensions are obtained from porcine valve leaflets, with minimal red blood cell contamination and debris. The successful execution of this protocol should yield viable cell populations ready for flow cytometric analysis, as indicated by viability staining. Flow cytometry staining of endothelial cells and immune cell markers will provide data on the different subpopulations. The obtained data will show the presence and proportion of GFP-positive cells and T cells in a transplanted valvular graft, allowing for comparison across different immunosuppression regimens. Combined, it will reflect the effect of different immunosuppression regimens post-transplant and systemic immune response to them. Limitations This protocol was optimized for flow cytometry analysis of CD31+ endothelial cells and CD3+ T cells from genetically modified green-fluorescent protein porcine partial heart transplant models. Semilunar valve leaflet digestion, antibody panels, and viability dyes were designed for this type of porcine model, especially accounting for GFP fluorescence. Working with additional antibody panels and other types of tissues will likely require optimization. This protocol is designed for extracellular antibody staining and is unsuitable for intracellular staining. This protocol provides rapid, easy, and effective flow cytometry analysis of porcine transplanted graft status with emphasis on CD31+ endothelial cells and CD3+ T cells; deeper characterization of these cell populations is limited. Moreover, the loss of cells during tissue digestion is a confounder that can be optimized but not eliminated entirely as seen in our initial experiment. This leads to a decreased cell population with each valve leaflet yielding approximately 2 million cells on average. Flow cytometry provides analysis and quantification of cell populations at single-cell resolution but does not provide any spatial information. We recommend performing histopathologic analysis on the same specimen sections alongside flow cytometry when investigating transplant immunobiology. Troubleshooting Problem 1 Red blood cell contamination in the tissue samples. Potential solution During sample procurement (Step 8), be very careful and precise while removing the leaflets. In case of any contamination, wash the tissue in ice-cold PBS to remove loosely associated blood. If visible contamination persists, use a sterile scalpel to dissect any unwanted cells. While RBC lysis buffer can be used to remove remaining RBCs, it was intentionally avoided in this protocol to reduce additional cellular stress. The digestion and mechanical processing steps already impose significant stress on the cells, and further treatment with lysis buffer may impact cell viability. RBC lysis buffer can be considered as an optional step if contamination is significant and interferes with downstream applications but may reduce overall cell recovery. Problem 2 Low cell viability. Potential solution Enzymatic digestion (Steps 9–10) is a critical determinant of sample viability and must be meticulously optimized. Both collagenase P concentration and digestion duration require precise calibration, as excessive enzyme levels or prolonged incubation will drastically reduce the overall viability of cells. CD31+ endothelial cells are particularly vulnerable to overdigestion due to their prolonged direct exposure to enzymatic activity. To preserve viability, immediately transfer samples to ice after the 37°C incubation phase and dilute with buffer solution to stop enzyme activity. Furthermore, enzyme quality directly impacts outcomes: use high-purity, activity-validated collagenase P, adhere strictly to manufacturer-recommended storage conditions, and avoid freeze-thaw cycles to maintain functional stability. Other general recommendations to increase cell viability in your samples: Immediately following tissue harvest, submerge specimens in ice-cold phosphate-buffered saline (PBS) to mitigate warm ischemia and halt metabolic degradation. Special care should be taken during centrifugation: for unfixed cells, centrifugal forces must not exceed 500 × g to avoid shear stress-induced membrane damage or cell lysis. Problem 3 Undetectable, insufficient, or inappropriate signals for cell surface markers. Potential solution Set up proper controls for reliable flow cytometry analysis (Step 21). Include unstained, single fluorochrome, and fluorescence minus one (FMO) controls to appropriately gate positive cell populations and compensate for spectral spillover. Titrate each antibody to determine optimal staining concentration, and perform an Fc-blocking step before or during cell staining to minimize non-specific binding. Once again, enzymatic digestion is a critical step since enzymes can cleave cell surface markers (steps 9-10). Enzyme concentration and timing of digestion should be finely optimized. If persistent marker loss occurs, consider substituting collagenase P with a gentler alternative, such as collagenase D, which exhibits distinct substrate specificity and may preserve vulnerable antigens. Post-digestion, validate marker retention using flow cytometry or functional assays to confirm cellular phenotype fidelity. Problem 4 Lack of statistical power due to too small sample size. Potential solution To achieve robust statistical significance, use a minimum of 3 animals per experimental group. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Taufiek Konrad Rajab (tkrajab@uams.edu). Technical contact Questions about the technical specifics of performing the protocol should be directed to the technical contact, Herra Javed (hjaved@uams.edu). Materials availability All materials used in the protocol are available commercially. Data and code availability This study did not generate/analyze datasets/code. Acknowledgments This study was supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute grant R41 HL169059; the American Association for Thoracic Surgery; The Brett Boyer Foundation; the Saving tiny Heart Society; the Emerson Rose Heart Foundation; philanthropy from senator Campbell; and the Arkansas Children’s Research Institute. Funding for the National Swine Resource and Research Center is from the National Institute of Allergy and Infectious Diseases, the National Institute of Heart, Lung, and Blood Institute, and the Office of the Director (U42OD011140). The authors are very grateful to Rushita A Bagchi and Melaney Gee for their help with sample logistics and revisions. The graphical abstract and Figure 1 were created using Biorender.com. Author contributions H.J. designed the experiments and performed the data analysis. H.J., Z.W., R.R., and E.C. performed the experiments. H.J. and A.F. wrote and edited the manuscript. L.S. assisted in laboratory experiments. J.L., D.I., K.W., M.B., and T.K.R. supervised the study and edited the manuscript. M.B. and T.K.R. edited the manuscript. H.J. performed the revision of the manuscript. Declaration of interests The authors declare no competing interests.